Website: http://www.nephrogenex.com/
NephroGenex is developing pharmaceuticals against certain kidney diseases.
VentureRadar Research / Company Website
Associated sectors:
Developing pharmaceuticals against certain kidney diseases; Healthtech; Biotech; Major Pharmaceuticals; Biotechnology; Therapeutics; Life Sciences;
Similar Companies:
Akebia Therapeutics
USA
Publicly Traded
Akebia Therapeutics is a biotech company that is based in Cincinnati, OH and was spun out of Procter & Gamble Pharmaceuticals in 2007. The Company's lead program, AKB-6548, is an orally bioavailable HIF-PH inhibitor that is in Phase 2 clinical trials for anemia associated with CKD. AKB-6548 potentially promises to be a safer, less expensive, orally dosed pharmaceutical to stimulate endogenous EPO production (www.akebia.com).
Praetego
USA
Privately Held
Praetego is a preclinical stage pharmaceutical company committed to addressing serious diabetic complications. Our novel and proprietary small molecule candidates target a common pathway in disease progression leading to serious complications. Our first target is Diabetic Peripheral Neuropathy (DPN)—a degenerative process of the nerves in the extremities. DPN affects approximately 50% of patients living with diabetes. Our candidates may also address other diabetic complications such as cognitive decline, nephropathy and retinopathy. Beyond DPN we are targeting Cognitive Decline, Nephropathy (Chronic Kidney Disease) and other serious diabetic complications.
Anthera Pharmaceuticals, Inc.
USA
Publicly Traded
Anthera Pharmaceuticals is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. Anthera has two product candidates, Sollpura, in Phase 3 development for Exocrine Pancreatic Insufficiency due to Cystic Fibrosis and blisibimod, in Phase 2 development for IgA nephropathy.
Alebund Pharmaceuticals
China
Privately Held
Alebund Pharmaceuticals is a Shangai, China-based biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions. The company has built a diversified and balanced pipeline of drug candidates targeting a range of renal diseases, including chronic kidney disease (CKD)/dialysis complications, IgA nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease (ADPKD). Its pipeline comprises both small-molecule and biologic assets. The most advanced product in the company’s pipeline has best-in-class potential in the treatment of hyperphosphatemia.
Conatus Pharmaceuticals
USA
Publicly Traded
Conatus Pharmaceuticals was founded in July 2005 by a cohesive and experienced team with a proven track-record in hepatology, infectious diseases and inflammation, including the divestment of Idun Pharmaceuticals to Pfizer in 2005. Conatus is building a drug pipeline in the areas of inflammation and liver disease, including infectious and metabolic diseases. Conatus Pharmaceuticals is located in San Diego, USA. Gilde is continuously looking for strong, committed and experienced managers and cohesive teams. Gilde decided to join the first financing round and acquire a high ownership position in the company. In 2006 Conatus Pharmaceuticals raised its 1st $27.5 m financning round which enabled to gain exclusive rights to a clinical stage drug candidate from Roche for the treatment of liver diseases associated with Hepatitis C infection and to implement a key value creating step in clinical trials.
Angios
Austria
Privately Held
Angios is developing new treatments for challenging vascular diseases using the vascular organoid model developed by the company’s founders. The vascular organoids allow the company to model human microvascular complications in the dish and thereby find new pathways associated with disease progression. Diseases affecting blood vessel functionality remain an unresolved global health problem, especially in diabetic patients who suffer from a multitude of vascular complications that can cause blindness, non-healing wounds and kidney failure. The company’s initial focus is diabetic retinopathy, which is a complication of type 1 and 2 diabetes. The condition is caused by chronic hyperglycemia and is the leading cause of preventable visual impairment and blindness in working-age adults. The company is also investigating the application of organoids for regenerative purposes. This could represent a new treatment strategy, especially for diabetic wounds, which in the worst cases can result in amputation.